Alpha Cognition's ZUNVEYL Poised for Breakthrough in Alzheimer's Treatment Market
Alpha Cognition has secured FDA approval for ZUNVEYL, a novel Alzheimer's treatment with improved patient tolerability, positioning itself for significant market penetration in long-term care settings with a potentially transformative approach to managing the disease.
Read the full story



























